Drugs / LY3007113
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01463631 | Dec 2011 → Dec 2013 | metastatic malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3007113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01463631 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL3544998 ↗1“p38 MAPK Inhibitor” NCT01463631 ↗ |
| Route | Oral | “Administered orally” NCT01463631 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL3544998 ↗ |